[go: up one dir, main page]

WO2007031879A3 - Méthodes permettant de réduire la gravité de la mucosite orale et gastro-intestinale - Google Patents

Méthodes permettant de réduire la gravité de la mucosite orale et gastro-intestinale Download PDF

Info

Publication number
WO2007031879A3
WO2007031879A3 PCT/IB2006/003538 IB2006003538W WO2007031879A3 WO 2007031879 A3 WO2007031879 A3 WO 2007031879A3 IB 2006003538 W IB2006003538 W IB 2006003538W WO 2007031879 A3 WO2007031879 A3 WO 2007031879A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogs
lipid
gastrointestinal mucositis
treating oral
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/003538
Other languages
English (en)
Other versions
WO2007031879A2 (fr
Inventor
Tetsu Kawano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Priority to AU2006290437A priority Critical patent/AU2006290437A1/en
Priority to CA002606727A priority patent/CA2606727A1/fr
Priority to JP2008510678A priority patent/JP2008540510A/ja
Priority to EP06831669A priority patent/EP1879597A2/fr
Publication of WO2007031879A2 publication Critical patent/WO2007031879A2/fr
Publication of WO2007031879A3 publication Critical patent/WO2007031879A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à des méthodes permettant de réduire la gravité de la mucosite orale et gastro-intestinale, qui consistent à administrer un antagoniste du récepteur Toll 4.
PCT/IB2006/003538 2005-05-13 2006-05-15 Méthodes permettant de réduire la gravité de la mucosite orale et gastro-intestinale Ceased WO2007031879A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2006290437A AU2006290437A1 (en) 2005-05-13 2006-05-15 Methods of reducing the severity of oral and gastrointestinal mucositis
CA002606727A CA2606727A1 (fr) 2005-05-13 2006-05-15 Methodes permettant de reduire la gravite de la mucosite orale et gastro-intestinale
JP2008510678A JP2008540510A (ja) 2005-05-13 2006-05-15 口腔粘膜炎及び胃腸粘膜炎の症状を緩和させる方法
EP06831669A EP1879597A2 (fr) 2005-05-13 2006-05-15 Méthodes permettant de réduire la gravité de la mucosite orale et gastro-intestinale

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68073305P 2005-05-13 2005-05-13
US60/680,733 2005-05-13

Publications (2)

Publication Number Publication Date
WO2007031879A2 WO2007031879A2 (fr) 2007-03-22
WO2007031879A3 true WO2007031879A3 (fr) 2007-10-04

Family

ID=37772612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/003538 Ceased WO2007031879A2 (fr) 2005-05-13 2006-05-15 Méthodes permettant de réduire la gravité de la mucosite orale et gastro-intestinale

Country Status (7)

Country Link
EP (1) EP1879597A2 (fr)
JP (1) JP2008540510A (fr)
KR (1) KR20080038085A (fr)
CN (1) CN101262870A (fr)
AU (1) AU2006290437A1 (fr)
CA (1) CA2606727A1 (fr)
WO (1) WO2007031879A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2554167T3 (es) * 2007-07-06 2015-12-16 Promedior Inc. Métodos y composiciones útiles en el tratamiento de mucositis
CN102159950B (zh) * 2008-06-13 2014-12-17 凯斯西部预备大学 治疗角膜炎症的组合物和方法
US8367316B2 (en) 2009-05-01 2013-02-05 Alfagene Bioscience, Inc. Human gastrointestinal stem cell-derived primary intestinal epithelial cell system and methods of use thereof
CA2868458A1 (fr) * 2012-03-28 2013-10-03 University Of Maryland, Baltimore Administration d'eritoran ou des sels pharmaceutiquement acceptables de celui-ci pour traiter des infections a orthomyxovirus
CN107669692B (zh) * 2017-09-07 2020-09-29 中国人民解放军第二军医大学 Mpla在制备电离辐射致肠道损伤防治药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013440A2 (fr) * 2001-08-10 2003-02-20 Eisai Co., Ltd. Traitement et prevention de maladies et de conditions associees a la proteine de choc thermique
US20030130212A1 (en) * 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130212A1 (en) * 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US20050215517A1 (en) * 1999-01-14 2005-09-29 Rossignol Daniel P Use of an anti-endotoxin drug in the prevention and treatment of disease
WO2003013440A2 (fr) * 2001-08-10 2003-02-20 Eisai Co., Ltd. Traitement et prevention de maladies et de conditions associees a la proteine de choc thermique
WO2003105861A1 (fr) * 2002-06-13 2003-12-24 Eisai Co., Ltd. Utilisation d'un medicament anti-endotoxinique pour le prevention et le traitement d'une affection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FORT MADELINE M ET AL: "A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease", JOURNAL OF IMMUNOLOGY, vol. 174, no. 10, May 2005 (2005-05-01), pages 6416 - 6423, XP002436852, ISSN: 0022-1767 *
SONIS S T: "A BIOLOGICAL APPROACH TO MUCOSITIS", JOURNAL OF SUPPORTIVE ONCOLOGY, BIOLINK COMMUNICATIONS,, US, vol. 2, no. 1, January 2004 (2004-01-01), pages 21 - 36, XP009053477, ISSN: 1544-6794 *

Also Published As

Publication number Publication date
WO2007031879A2 (fr) 2007-03-22
JP2008540510A (ja) 2008-11-20
EP1879597A2 (fr) 2008-01-23
CA2606727A1 (fr) 2007-03-22
AU2006290437A1 (en) 2007-03-22
KR20080038085A (ko) 2008-05-02
CN101262870A (zh) 2008-09-10

Similar Documents

Publication Publication Date Title
WO2006058236A3 (fr) Composition et methode pour traiter des affections neurologiques
WO2005082925A3 (fr) Nouvel agoniste steroidien pour fxr
WO2008057579A3 (fr) Formes dosifiées et co-administration d'un agoniste opioïde et d'un antagoniste opioïde
WO2007019439A3 (fr) Compositions de copolymere sequence et utilisations de ces dernieres
WO2006058059A3 (fr) Procede et composition pour administrer un antagoniste du recepteur de nmda a un sujet
IL184126A0 (en) Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release
MY153975A (en) Pyridine derivatives as s1p1/edg1 receptor modulators
WO2005079756A3 (fr) Methodes et compositions de traitement de troubles psychiatriques
WO2009025876A8 (fr) Formes cristallines de chlorhydrate d'erlotinib et formulations de celles-ci
IL182090A (en) Pyrimidines 6,2 – Transformed, 4 – Amino – MonomersConverted @ as antagonists to a 2D prostaglandin receptor
WO2007027527A3 (fr) Composes d'isoindole-imide et compositions renfermant ceux-ci et procedes d'utilisation de ceux-ci
WO2007076260A3 (fr) Agonistes de recepteur de farnesoide x
PL1740156T3 (pl) Sposób wytwarzania zabezpieczonej przed nadużyciem, stałej postaci aplikacyjnej
WO2009084024A3 (fr) Procédé pour la préparation de r-sitagliptine et de ses sels pharmaceutiquement acceptables
MY150736A (en) Mousse
WO2006138503A8 (fr) Nouveaux schémas posologiques pour contraceptifs oraux monophasiques
WO2008051564A3 (fr) Formes cristallines d'hydrochlorure de palonosetron
WO2009059143A3 (fr) Utilisation d'antagonistes du récepteur 4 de type toll (tlr4) pour le traitement ou la prévention de troubles ostéoarthritiques
WO2007031879A3 (fr) Méthodes permettant de réduire la gravité de la mucosite orale et gastro-intestinale
GB0500815D0 (en) Method for preparation of 10, 11-dihydro-10-hydroxy-5H-divenz/b,f/azepine-5-carboxamide
WO2007078271A3 (fr) Comprimes a desintegration orale de lansoprazole
WO2007105223A3 (fr) Procedes de diagnostic de troubles lipidiques associes a pon1-hdl
WO2004071465A3 (fr) Procedes et trousses a utiliser pour diagnostiquer et traiter un endotoxemie
WO2007075980A3 (fr) Comprimes de lansoprazole se desintegrant oralement
WO2007007182A3 (fr) Formes galeniques solides d'agent antiepileptique

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006290437

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006290437

Country of ref document: AU

Date of ref document: 20060515

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006290437

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2606727

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008510678

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200680016561.4

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006831669

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077028786

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWP Wipo information: published in national office

Ref document number: 2006831669

Country of ref document: EP